TRANSEURO
NEURAL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH PARKINSON’S DISEASE
| Coordinatore | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.transeuro.org.uk/ |
| Totale costo | 16˙142˙794 € |
| EC contributo | 11˙994˙095 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | coordinator | 3˙808˙371.15 |
| 2 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 2˙005˙726.00 |
| 3 |
CARDIFF UNIVERSITY
Organization address
address: Newport Road 30-36 contact info |
UK (CARDIFF) | participant | 1˙114˙980.00 |
| 4 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 982˙706.24 |
| 5 |
IMANOVA LIMITED
Organization address
address: PRIMEROSE STREET 20 contact info |
UK (LONDON) | participant | 789˙999.80 |
| 6 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 756˙201.00 |
| 7 |
SKANE LANS LANDSTING
Organization address
city: KRISTIANSTAD contact info |
SE (KRISTIANSTAD) | participant | 671˙759.99 |
| 8 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 636˙024.40 |
| 9 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 369˙600.00 |
| 10 |
DANDO WEISS & COLUCCI LIMITED
Organization address
address: LOWER BRISTOL ROAD MINERVA HOUSE contact info |
UK (BATH) | participant | 310˙162.14 |
| 11 |
LIFE SCIENCE GOVERNANCE INSTITUTE
Organization address
address: Schottenfeldgasse 29 contact info |
AT (vienna) | participant | 213˙664.98 |
| 12 |
LIFE TECHNOLOGIES LIMITED
Organization address
address: Fountain Drive 3 contact info |
UK (Paisley) | participant | 173˙600.00 |
| 13 |
Inomed Medizintechnik GmbH
Organization address
address: Tullastrasse 5a contact info |
DE (Teningen) | participant | 73˙800.00 |
| 14 |
Cambridge Cognition LTD
Organization address
address: "TUNBRIDGE COURT TUNBRIDGE LANE, BOTTISHAM CAMBS" contact info |
UK ("Bottisham, Cambridge") | participant | 61˙650.00 |
| 15 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 25˙849.30 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'There are currently no cures for Parkinson's disease (PD) but one of the most effective reparative therapies in patients to date has been with allotransplants of dopamine (DA) neuroblasts obtained from fetal ventral mesencephalic (VM) tissue. However, this cell transplantation approach has given inconsistent results, with some patients doing extremely well and coming off anti-PD medication for years, whilst others have shown no or only modest clinical improvements, and in some cases also developed severe, off-state graft-induced dyskinesias (GIDs). The reasons behind this heterogeneity of outcomes, and the emergence of GIDs in particular, need to be better understood, not least in the perspective of the rapid advances that are now being made in the development of stem-cell based therapies. There is therefore an urgent need to revisit the trials that have already been done with fetal VM tissue in PD patients, with the expectation that a critical reassessment can form the basis for an optimised and more standardised procedure that will translate into more consistently efficacious transplants with minimal side-effects. Over the last two years a group of international experts, including the key investigators of the previous European and North American trials, has been re-examining the outcome of these trials as well as reviewing the results obtained from recent and ongoing animal experimental studies, and identified a number of weaknesses that may explain the inconsistent outcome in previous trials. As a result of these discussions, the group has agreed to join forces in a new round of experimental work and cell therapy trials in PD, based on a new jointly developed protocol where all these factors are taken into account. In the first instance fetal VM tissue containing mesencephalic DA neuroblasts will be used, with the expectation that this will pave the way for bigger trials using dopaminergic neurons derived from stem cells.'
Introduzione (Teaser)
Current research is fine-tuning stem cell-based treatments to achieve consistent benefits for patients with neurodegenerative diseases such as Parkinson's disease (PD).